乌鸦传媒

Promising findings from various clinical trials at the San Antonio Breast Cancer Symposium (SABCS) have the breast cancer research community buzzing about the future of antibody drug conjugates (ADCs) in metastatic disease. As we ring in the new year, what are some of the most exciting therapies we should expect to change practice in 2024?

In this video, Yuan Yuan, MD, director of breast oncology at Cedars-Sinai Cancer Center in Los Angeles, offers her take on the landscape of current and future treatments in metastatic breast cancer and discusses ongoing projects at her institution.

The following is a transcript of her remarks:

I think what's in the field is we have many questions regarding antibody drug conjugates, how to sequence them in HR [hormone receptor]-positive or triple-negative disease. And also with now new FDA approval of the AKT inhibitor, capivasertib [Truqap] and recent approval of estrogen receptor oral SERD [selective estrogen receptor degrader] elacestrant [Orserdu].

So I think embracing the situation, or complex scenario, of how to sequence therapy -- how to get the most out of the patients and how to also help patients to understand better. Sometimes the discussion becomes very complex, so we're hoping to get guidance from evidence-based [data], but likely not every question will have an evidence-based answer.

We're building up our portfolio, besides these metastatic triple-negative breast cancer, my colleague Dr. Monica Mita, is also running an all-comers metastatic cancer trial looking at breast cancer patients [with] a feature of HRD, homologous recombination defect. And then using the combination of olaparib [Lynparza] in combination with [pembrolizumab (Keytruda)] in all comers, including HER2-negative/ER [estrogen receptor]-positive, triple-negative disease. So that's an . Patients are doing well as well.

Comment